|
|
|
|
|
04.06.25 - 14:31
|
Dominari Holdings Issues Letter to Shareholders (PR Newswire)
|
|
|
NEW YORK, June 4, 2025 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) today issued the following letter to shareholders: Dear Shareholders, I am very proud of what Dominari Securities, our wholly owned subsidiary, accomplished in less than three (3) years and wish to take this......
|
|
|
|
|
|
|
28.05.25 - 14:33
|
Dominari Holdings Set to Join Russell Microcap® Index (PR Newswire)
|
|
|
NEW YORK, May 28, 2025 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH), is set to join the Russell Microcap® Index at the conclusion of the 2025 Russell indexes annual reconstitution, effective after the US market opens on June 30, according to a preliminary list of additions posted......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.03.25 - 13:03
|
Dominari Holdings Reports Preliminary FY 2024 Financial Results (PR Newswire)
|
|
|
2024 Revenue Surges to Approximately $19 Million as Company Executes Growth and Expansion Strategy NEW YORK, March 28, 2025 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company" or "Dominari") today announced its preliminary, unaudited revenue results for the full year......
|
|
|
27.02.25 - 13:02
|
XFRA : BP2A: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
DOMINARI HOLDINGS DL-,01 BP2A US0088753043
AB/FROM ONWARDS 27.02.2025 12:43 CET...
|
|
|
|
|
|
|
|
|
21.02.25 - 14:21
|
Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025 (Business Wire)
|
|
|
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”), has engaged Dominari Securities LLC as lead underwriter for Pearsanta's planned initial public offering (IPO). The proposed IPO, advised by Dominari Securities, is intended to support Pearsanta's U.S. and international commercial launch efforts and further advance its Mitomic® Technology platform for early cancer detection and diagnosis.
Pearsanta is developing a non-invasive blood-based test designed to detect cancer at earlier stages when treatment outcomes are more favorable. The Company's proprietary Mitomic® Technology leverages mitochondrial DNA deletions as biomarkers for disease detection, providing a unique approach to identifying malignancies. We believe that Pearsanta's biomarker portfolio covers many high-clinical need cancers, wi...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
